List of Small Molecule Pharmaceuticals Companies in Spain - 26

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

Affirma Biotech is a privately owned preclinical company that develops new orally available immunotherapeutic drugs for the treatment of severe infections.

Anapharm Bioanalytics is a customer-focused bioanalytical CRO specialized in small and large molecule bioanalysis. Led by a team with over 30 years' experience in method development, validation and sample analysis, we support drug development programs for the pharmaceutical, biotechnological and generic industries worldwide. Equipped with state-of-the-art LC-MS/MS and LBA technology platforms, Anapharm Bioanalytics provides an array of services including PK studies, biomarker testing and immunogenicity assays throughout preclinical and clinical stages. Our global network of partners allows us to provide full-service outsourcing solutions to conduct preclinical, Phase I-IV clinical trials, and bioequivalence studies for international registration. Our clients benefit from a deep scientific expertise combined with a robust quality system. All our activities are compliant with GLP and GCP, having undergone 20 regulatory inspections by the FDA, several EU Health Authorities and ANVISA (Brazil). Whether your drug candidate is a new chemical entity, a new biologic, a generic or a biosimilar, do not hesitate to contact us at info@anapharmbioanalytics.com.

AntalGenics is a biotechnological company focused on the design and development of new active molecules for biomedical and dermocosmetic applications MISSION To discover and develop innovative leads in the field of sensory neurobiology with pharmaceutical and dermocosmetical applications. VISION To transform our scientific results into products and services for society and to improve the quality of life.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

Curapath is a CDMO with expertise in developing novel drug delivery systems (DDS). What sets us apart is our analytical expertise in the formulation and manufacturing of Lipid nanoparticles (LNP) and Polymer nanoparticles (PNP). When you start working with Curapath, we can support your entire therapeutic journey from development to IND. Curapath supports GMP manufacturing of Drug Substance and Drug Product for clinical trial material. We provided unmatched technical support and analytical expertise in the custom design, development, and end-to-end GMP manufacturing of polymer and lipid-based drug delivery systems to support cell therapy, gene therapy, and vaccine delivery. For over a decade, Curapath has supported drug innovators in developing stealth shielding polymers (polyaminoacids), functional polymer & lipid excipients, linkers for bioconjugation, and API polymers used for therapeutics. Our history of success makes Curapath the right partner to drive your therapeutic development. We deliver consultative hands-on guidance from preclinical development through commercial-scale GMP manufacturing. Curapath is a knowledgeable partner you can trust to move fast, manufacture smart, and provide support through your drug development journey, accelerating your speed to the clinic. We help our partners solve even the most complex drug delivery challenges.

We are ESTEVE, a global pharmaceutical company with one defined mission: improving lives. Founded in 1929 and headquartered in Barcelona, we have a strong international footprint, with affiliates across Spain, Portugal, Italy, Germany, France, the UK, and the USA. As a leader in speciality pharmaceuticals, we focus on creating highly specialized treatments that address significant unmet medical needs. Our expertise extends to Contract Manufacturing, where we produce Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China. Driven by our core values—people matter, transparency, and accountability—we’re committed to innovation, quality, and making a meaningful difference in healthcare. Because we care not only about what we do, but also about how we do it. #ESTEVE #AdvancingHealthTogether #Makeitsustainable #Pharmaceuticals #Innovation #SpecialtyPharma #APIs

At Ferrer, we focus on identifying projects with differential value. The R&D team aims to develop and deliver transformative therapeutic solutions for people living with severe and debilitating diseases. Innovation is an inherent part of our pharmaceutical development, and we have always upheld our commitment in searching for and developing new treatment alternatives aimed at addressing unmet medical needs in order to improve the patients' quality of life and creating value for physicians, health systems and society at large. We do this in two main areas: Pulmonary vascular and interstitial lung diseases & Neurological disorders

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and other innovative biopharmaceutical solutions.

IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). We are currently focused on exploiting new mechanisms of action to treat cancer diseases. Our efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, we have built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.

INMUNOTEK is a pharma company which researches, develops, manufactures and distributes therapeutic vaccines in the fields of allergy, infectious diseases and cancer. In addition, the company develops, manufactures and sells medical devices. INMUNOTEK was founded in 1992 with the mission of improving the quality of life of patients and providing value to healthcare professionals, by creating innovative, safe and effective products. INMUNOTEK's products are sold in both Spain and in more than 50 other countries around the world through our subsidiaries, sales offices and exclusive distributors. Our two production centres are based in the towns of San Sebastián de los Reyes and Alcalá de Henares (Madrid, Spain).

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers`​ needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.

Mikrobiomik is a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome. Our vision We aspire to be the first company in the world to market a medicine based on faecal microbiota in the EU. To that end, we are holding talks with both the EMA (European Medicines Agency) and the AEMPS (Spanish Agency for Medicines and Health Products) with a view to establishing protocols on the regulatory requirements for securing an MAA (Marketing Authorization Application) via centralised procedure. Our values Mikrobiomik seeks to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome through excellence in its processes, empathising with chronic patients for whom no curative treatments are available, always from the perspective of networking with all stakeholders in the sector.

Oncostellae is a biotech startup founded in 2013 by a team of medicinal chemists and pharmacologists. The company focuses on the discovery of new pharmaceutically active compounds and their development, with a particular emphasis on small-molecule drugs with innovative scaffolds that modulate clinically validated therapeutic targets. Oncostellae is a clinical-stage biotech company that is owned by private and institutional investors, and it is involved in the discovery and development of new pharmaceutical compounds.

A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme.

Palobiofarma S.L is a Spanish biotechnology company founded in 2006 by a group of scientists with experience in drug discovery in several pharmaceutical fields. The company is focused on developing innovative treatments for serious diseases and has been involved in various clinical trials for its most advanced compounds.

Reig Jofre is a Spanish pharmaceutical company founded in 1929 in Barcelona. It is currently led by the third generation of the Reig family and is listed on the Spanish Stock Exchange. The company employs over 1,100 people and operates in more than 70 countries through subsidiaries and partnerships. Reig Jofre specializes in pharmaceutical manufacturing, research and development, and commercialization, with production centers located in Barcelona, Toledo, and Sweden. The company offers contract manufacturing services, focusing on sterile injectables, beta-lactam antibiotics, and lyophilized products. It has partnered with Janssen to produce the COVID-19 vaccine and collaborates on various co-development projects. Reig Jofre's product range includes antibiotics, dermatology products utilizing patented technology, hospital injectables, and over-the-counter supplements. Recent developments include the opening of a new manufacturing plant in Barcelona and expansion into the South Korean market.

Rovi is a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Their operations encompass the marketing of both their own and licensed products and the provision of services, such as production, filling and packaging, to other companies.

Nuestro equipo se dedica al desarrollo y comercialización de productos para la salud y el bienestar de las personas, a través de un servicio integral, soluciones innovadoras y productos de máxima calidad bajo normas GMP en: autocuidado, medicina de prescripción, cuidados hospitalarios y servicios especializados para terceros.

Smart Vitamins is a Spin-Off company from the University of Santiago de Compostela that has developed an innovative technology based in essential nutrients and nanocarriers for treating autoimmune diseases.

International biomedical leaders in inflammasome R&D. Viva In Vitro defines themselves as a cutting-edge and impactful company in the field of research. The company has attracted the confidence of investors and international medical institutions, and has been certified by ENISA as an emerging company within the framework.